Table 6. Trends in primary and relapse VL in Southern Sudan (1999–2007).
| 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | APCh | ||
| Relapse VL a | 4.1% | 6.3% | 2.8% | 2.6% | 5.9% | 8.5% | 4.0% | 12.8% | 7.6% | 11.4% (−3.4% to 28.5%) | |
| SSG b | 99.5% | 100.0% | 99.9% | 52.3% | 9.6% | 31.6% | 8.2% | 6.7% | 0.0% | - | |
| SSG/PM b | 0.5% | 0.0% | 0.1% | 47.7% | 90.4% | 68.4% | 91.8% | 93.3% | 100.0% | - | |
| Deaths c | 13.5% | 10.0% | 7.4% | 4.4% | 5.6% | 3.6% | 4.2% | 2.9% | 2.4% | 18.1% (−22.5% to −13.4%) | |
| Mean time-to-presentation of VL relapse patients (months) d | 3.0 | 3.3 | 2.2 | 2.7 | 1.8 | 2.1 | 1.8 | 2.4 | 1.6 | −6.7% (−11.3% to −1.8%) | |
| Mean time-to-presentation of primary VL patients (months) e | 2.8 | 2.4 | 2.2 | 1.8 | 1.6 | 1.7 | 1.7 | 1.9 | 1.2 | −7.7% (−3.8% to −11.6%) | |
| Hackett Grade ≥3 f | 34.4% | 32.5% | 25.3% | 18.0% | 20.0% | 22.6% | 16.4% | 15.0% | 16.0% | −9.6% (−13.5% to −5.5%) | |
| Interval between primary and relapse VL (days) g | median | 111 | 86 | 109 | 104 | 101 | 77 | 78 | 78 | 48 | - |
| (range) | (33–198) | (24–183) | (23–250) | (34–623) | (19–1358) | (27–145) | (45–310) | (22–240) | (48) | ||
| patients | n = 13 | n = 4 | n = 18 | n = 40 | n = 51 | n = 13 | n = 19 | n = 7 | n = 1 |
a
from MSF summary statistics (expressed as proportion of patients treated for primary VL, N = 11,319).
b
from MSF treatment records (proportion of primary VL patients receiving this treatment, N = 8,521).
c
from MSF summary statistics (expressed as proportion of all patients treated, N = 12,924).
d
from MSF treatment records (duration of illness self-reported by VL relapse patients, N = 589).
e
from MSF treatment records (duration of illness self-reported by primary VL patients, N = 7,841).
f
from MSF treatment records (spleen size measured in primary VL patients, N = 8,494).
g
from MSF treatment records (interval between discharge and re-admission, N = 166).
h
Annual Percentage Change (95% confidence interval) estimated from join-point regression.